EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial

Yuan He, Huiquan Liu, Xiaoyang Li, Jianguo Wang, Haibo Wu, Hangcheng Zhou, Xueru Wang, Jingjing Cheng, Jun Ma, Xinyu Mei, Jieyong Tian, Dong Qian

European Journal of Cancer · 2025-10 · 228 · 115717

DOI: 10.1016/j.ejca.2025.115717 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2025-10. Verfasst von Yuan He und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEsophageal Squamous Cell CarcinomaEsophageal NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedProspective StudiesChemoradiotherapy

Stichwörter der Autor:innen

CamrelizumabChemoradiationEsophageal squamous cell carcinomaNimotuzumab

Substanzen

Antibodies, Monoclonal, Humanizedcamrelizumabnimotuzumab

Autor:innen und Institutionen

  • Department of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China; Core Facility Center, The First…
  • Department of Pathology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China.
  • Department of Thoracic surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China.
  • Department of Thoracic surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine. University of Science and Technology of China, Hefei, Anhui 230001, China. Electronic address: tjyong77@sina…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

He, Y., Liu, H., Li, X., Wang, J., Wu, H., Zhou, H., Wang, X., Cheng, J., Ma, J., Mei, X., Tian, J., & Qian, D. (2025). Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. European Journal of Cancer, 228, 115717. https://doi.org/10.1016/j.ejca.2025.115717

Vancouver

He Y, Liu H, Li X, Wang J, Wu H, Zhou H, et al. Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial. European Journal of Cancer. 2025;228:115717. doi:10.1016/j.ejca.2025.115717

BibTeX
@article{He2025,
  author = {He, Yuan and Liu, Huiquan and Li, Xiaoyang and Wang, Jianguo and Wu, Haibo and Zhou, Hangcheng and Wang, Xueru and Cheng, Jingjing and Ma, Jun and Mei, Xinyu and Tian, Jieyong and Qian, Dong},
  title = {Neoadjuvant chemoradiation with camrelizumab and nimotuzumab for initially inoperable esophageal squamous cell carcinoma: A single-arm phase 2 trial},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {228},
  pages = {115717},
  doi = {10.1016/j.ejca.2025.115717}
}
Kostenlos starten →